公司资料
Pasithea Therapeutics 股价、新闻与催化剂
- 股票代码:
- KTTA
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
0.51 USD (+3.41%)
收盘价
最后更新: 2026年9月17日
21.6M USD
市值
股价为何变动
截至 2026年9月17日，KTTA 上涨 3.41%，收于 $0.5067。当前新闻监测窗口内未发现新的同公司新闻。
公司概览
业务概览
Pasithea Therapeutics is a biotechnology company focused on neuropsychiatric disorders and inflammation-linked biology. Its story centers on developing treatments for difficult CNS conditions with limited effective options.
所在地与行业分类
Pasithea is headquartered in the United States and listed on NASDAQ. It sits in small-cap biotechnology with a neuroscience angle.
商业模式特征
The company depends on clinical progress, translational validation, and capital efficiency. Investors generally watch early data, program resets, and whether the company can maintain a coherent development strategy.
生物医药行业定位
Pasithea occupies a speculative neuroscience niche within biotech. The stock tends to be driven by the market's willingness to underwrite a narrow CNS thesis.
未来催化剂
- Pasithea’s catalysts are oncology and CNS programs, along with any strategic step that clarifies what the company is really building. The stock remains highly dependent on a cleaner path.
近期新闻
新闻标题由机器翻译，详情为英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。